Physician profile

Jessica Rivera

Family · Clemson, SC

NPI 1437598588

$6,431.87

in general payments reported to CMS, 2019-2025

44 companies · $1,758 in 2025

The $1,758 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).

See the full distribution for Family

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$5,187.09

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $1,541.66 2021-2025
Lilly USA, LLC $931.04 2021-2025 Mounjaro, Zepbound, Jardiance
Teva Pharmaceuticals USA, INC. $620.81 2022-2025 Austedo Xr, Austedo Xr, Austedo
Pfizer INC. $564.38 2021-2025
Novo Nordisk INC $364.28 2021-2025 Ozempic, Rybelsus, Wegovy
Glaxosmithkline, LLC. $222.78 2021-2024 Trelegy Ellipta, Arexvy, Shingrix
Lundbeck LLC $167.32 2024-2025 Vyepti, Rexulti
Eisai INC. $167.16 2021-2025
Xeris Pharmaceuticals, INC. $153.63 2023-2025 Gvoke Hypopen
Exact Sciences Corporation $130.14 2023-2025 Cologuard Collection Kit, The Cologuard Plus Collection Kit
Argenx US, INC. $129.42 2023-2025 Vyvgart Hytrulo, Vyvgart
Otsuka America Pharmaceutical, INC. $126.55 2021-2024 Nuedexta, Rexulti
Neurocrine Biosciences, INC. $121.32 2023-2025 Ongentys
Astrazeneca Pharmaceuticals LP $113.39 2024-2025 Breztri, Airsupra
Dexcom, INC. $103.37 2021-2023 Dexcom G6 Transmitter
Show all 44 companies
CompanyGeneral paymentsYearsTop products
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $64.23 2025 Caplyta
Neurelis, INC. $62.13 2025 Valtoco
Alexion Pharmaceuticals, INC. $61.76 2024-2025 Ultomiris
Cranial Technologies, INC $59.69 2023-2025 Doc Band
Vanda Pharmaceuticals INC. $54.74 2024-2025 Fanapt, Hetlioz
Axsome Therapeutics, INC. $50.06 2025 Symbravo
Ucb, INC. $46.74 2023-2025 Briviact
Idorsia Pharmaceuticals US INC $46.11 2022-2024 Quviviq
Tg Therapeutics, INC. $45.90 2025
Genzyme Corporation $42.84 2025
Ultragenyx Pharmaceutical INC. $41.05 2021-2022
Biohaven Pharmaceutical Holding Company LTD. $40.60 2022
Boehringer Ingelheim Pharmaceuticals, INC. $39.96 2022-2023 Tradjenta, Synjardy
Amgen INC. $37.47 2021-2023 Aimovig
Csl Behring $30.30 2025 Hizentra
Abiomed $25.81 2024 Impella
Daiichi Sankyo INC. $25.41 2024 Injectafer
Janssen Pharmaceuticals, INC $23.66 2021
Genentech USA, INC. $22.67 2025 Ocrevus
Sk Life Science, INC. $21.25 2025
Kyowa Kirin, INC. $17.89 2023 Nourianz
Shield Therapeutics INC $17.29 2025
Merck Sharp & Dohme LLC $16.61 2025 Lagevrio
Impel Pharmaceuticals INC. $16.03 2023 Trudhesa
Phadia US INC. $14.44 2021
Sanofi Pasteur INC. $13.71 2022
Esperion Therapeutics, INC. $12.60 2021
Ibsa Pharma INC. $12.45 2021
Abbott Laboratories $11.22 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jessica Rivera

$6,431.87

in general payments reported 2019-2025

Years
2021-2025
Top company
Abbvie INC.
Context
The $1,758 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).

https://glasscript.com/doctor/10866158/jessica-rivera

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.